Literature DB >> 29455466

The effects of interleukin-33 on airways collagen deposition and matrix metalloproteinase expression in a murine surrogate of asthma.

Gao An1, Xin Zhang1, Wenjun Wang2, Qiong Huang1, Yan Li1, Shan Shan1, Chris J Corrigan3, Wei Wang1, Sun Ying1.   

Abstract

It has been suggested that interleukin-33 (IL-33) plays an important role in the pathogenesis of asthma through a variety of pathways, but its role in airways fibrosis in asthma has not been fully elucidated. In the present study we evaluated changes in the expression of extracellular matrix proteins (ECMs) as well as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in an IL-33-induced, antigen-independent murine surrogate of asthma as well as a conventional surrogate employing per-nasal challenge of mice previously sensitized to produce an IgE response to ovalbumin (OVA). In addition, in in vitro experiments we explored the direct effects of IL-33 on the proliferation and function of murine fibroblasts. Per-nasal administration of IL-33 alone was sufficient to induce airways deposition of ECMs, including collagens I, III, V and fibronectin, to a degree comparable with that observed in the OVA-sensitized and challenged mice. These changes were associated with a local imbalance between the expression of extracellular MMPs and TIMPs. Per-nasal challenge of mice with IL-33 also induced elevated airways expression of connective tissue growth factor and fibroblast growth factor receptor 4, two key facilitators of local fibrosis, again to a degree compatible with that observed in OVA-sensitized and challenged mice. Deletion of the ST2 gene, which encodes the IL-33 receptor, abrogated these fibrotic changes in the airways in the OVA surrogate. In vitro, IL-33 significantly increased the proliferation and expression of collagen III by murine lung fibroblasts. These data suggest that direct exposure of murine airways to IL-33 is able to induce local fibrotic changes, at least partially through effects of signalling through the IL-33/ST2 axis on fibroblast function and local expression of MMPs and their inhibitors, and other fibrosis-related proteins.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; fibrosis; interleukin-33; pathogenesis; remodelling

Year:  2018        PMID: 29455466      PMCID: PMC6050212          DOI: 10.1111/imm.12911

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells.

Authors:  Ralf Weiskirchen; Frank Tacke
Journal:  Cell Mol Immunol       Date:  2016-12-26       Impact factor: 11.530

2.  Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.

Authors:  Sonali Sonnylal; Xu Shi-Wen; Patricia Leoni; Katherine Naff; Caroline S Van Pelt; Hiroyuki Nakamura; Andrew Leask; David Abraham; George Bou-Gharios; Benoit de Crombrugghe
Journal:  Arthritis Rheum       Date:  2010-05

Review 3.  IL-33: biological properties, functions, and roles in airway disease.

Authors:  Li Yin Drake; Hirohito Kita
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

4.  Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production.

Authors:  Futoshi Matsui; Stephen K Babitz; Audrey Rhee; Karen L Hile; Hongji Zhang; Kirstan K Meldrum
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-19

5.  A novel IL-1 family cytokine, IL-33, potently activates human eosinophils.

Authors:  W Brett Cherry; Juhan Yoon; Kathleen R Bartemes; Koji Iijima; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2008-06       Impact factor: 10.793

Review 6.  Regulation of matrix metalloproteinases: an overview.

Authors:  Sajal Chakraborti; Malay Mandal; Sudip Das; Amritlal Mandal; Tapati Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

7.  Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis.

Authors:  Norihiko Sakai; Miki Nakamura; Kenneth E Lipson; Taito Miyake; Yasutaka Kamikawa; Akihiro Sagara; Yasuyuki Shinozaki; Shinji Kitajima; Tadashi Toyama; Akinori Hara; Yasunori Iwata; Miho Shimizu; Kengo Furuichi; Shuichi Kaneko; Andrew M Tager; Takashi Wada
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

8.  IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice.

Authors:  Dong Li; Rodrigo Guabiraba; Anne-Gaëlle Besnard; Mousa Komai-Koma; Majid S Jabir; Li Zhang; Gerard J Graham; Mariola Kurowska-Stolarska; Foo Y Liew; Charles McSharry; Damo Xu
Journal:  J Allergy Clin Immunol       Date:  2014-06-27       Impact factor: 10.793

9.  Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.

Authors:  Kosuke Hamai; Hiroshi Iwamoto; Nobuhisa Ishikawa; Yasushi Horimasu; Takeshi Masuda; Shintaro Miyamoto; Taku Nakashima; Shinichiro Ohshimo; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori; Nobuoki Kohno
Journal:  Dis Markers       Date:  2016-05-17       Impact factor: 3.434

10.  Nasal administration of interleukin-33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate.

Authors:  Shan Shan; Yan Li; Jingjing Wang; Zhe Lv; Dawei Yi; Qiong Huang; Chris J Corrigan; Wei Wang; Zhang Quangeng; Sun Ying
Journal:  Immunology       Date:  2016-03-08       Impact factor: 7.397

View more
  10 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

2.  KIF2A decreases IL-33 production and attenuates allergic asthmatic inflammation.

Authors:  Zhengxia Wang; Jingjing Wu; Jingxian Jiang; Qiyun Ma; Meijuan Song; Tingting Xu; Yanan Liu; Zhongqi Chen; Yanmin Bao; Mao Huang; Mingshun Zhang; Ningfei Ji
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-19       Impact factor: 3.373

Review 3.  Interleukin-33: Its Emerging Role in Allergic Diseases.

Authors:  Wen Ding; Gui-Lin Zou; Wei Zhang; Xing-Ning Lai; Hou-Wen Chen; Li-Xia Xiong
Journal:  Molecules       Date:  2018-07-09       Impact factor: 4.411

Review 4.  Contributions of IL-33 in Non-hematopoietic Lung Cells to Obstructive Lung Disease.

Authors:  Li Y Drake; Y S Prakash
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

5.  IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF Expression in Vascular Endothelial Cells.

Authors:  Jie Liu; Wang Wang; Lei Wang; Shihao Chen; Bo Tian; Kewu Huang; Chris J Corrigan; Sun Ying; Wei Wang; Chen Wang
Journal:  EBioMedicine       Date:  2018-06-18       Impact factor: 8.143

6.  Piperlongumine reduces ovalbumin‑induced asthma and airway inflammation by regulating nuclear factor‑κB activation.

Authors:  Chun Lu; Bing Zhang; Tingting Xu; Wenxin Zhang; Bin Bai; Zhongxiang Xiao; Liqin Wu; Guang Liang; Yali Zhang; Yuanrong Dai
Journal:  Int J Mol Med       Date:  2019-08-21       Impact factor: 4.101

7.  Baicalein attenuates OVA-induced allergic airway inflammation through the inhibition of the NF-κB signaling pathway.

Authors:  Tingting Xu; Xiangting Ge; Chun Lu; Wei Dai; Hongjin Chen; Zhongxiang Xiao; Liqin Wu; Guang Liang; Songmin Ying; Yali Zhang; Yuanrong Dai
Journal:  Aging (Albany NY)       Date:  2019-11-06       Impact factor: 5.682

8.  LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity.

Authors:  Doumet Georges Helou; Pedram Shafiei-Jahani; Benjamin P Hurrell; Jacob D Painter; Christine Quach; Emily Howard; Omid Akbari
Journal:  J Allergy Clin Immunol       Date:  2021-06-16       Impact factor: 10.793

9.  Epithelial-Mesenchymal Transition in Asthma Airway Remodeling Is Regulated by the IL-33/CD146 Axis.

Authors:  Zhixiao Sun; Ningfei Ji; Qiyun Ma; Ranran Zhu; Zhongqi Chen; Zhengxia Wang; Yan Qian; Chaojie Wu; Fan Hu; Mao Huang; Mingshun Zhang
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

Review 10.  Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment.

Authors:  Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Front Physiol       Date:  2022-01-03       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.